Literature DB >> 7708924

Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens.

T Amano1, H Matsubayashi, T Momiyama, K Ishihara, N Todo, M Sasa.   

Abstract

1. The effects of a newly synthesized quinolinone derivative, 7-(4-[4-(2,3-dichlorophenlyl)-1-piperazinyl]butyloxy)-3,4-di hydro-2-(1H)- quinolinone (OPC-14597), an antipsychotic drug, on neuronal activities of the nucleus accumbens (Acc) were investigated in rats anesthetized with chloral hydrate using a microiontophoretic method. 2. Spikes elicited by stimulation of the parafascicular nucleus (Pf) of the thalamus were extracellularly recorded in the Acc neuron of chloral hydrate-anesthetized adult Wistar rats using a glass microelectrode attached along a seven-barreled micropipette, each of which was filled with dopamine, OPC-14597, SKF 38393 (D1 receptor agonist), quinpirole (D2 receptor agonist) and 2M NaCl. The drugs were microiontophoretically applied to the target neurons recorded. 3. Effects of the drugs on the Acc neurons activated monosynaptically by stimulation of the Pf were examined. Spikes elicited by Pf stimulation were inhibited by iontophoretic application of dopamine, SKF 38393 and quinpirole in a dose-dependent manner. 4. Microiontophoretic application of OPC-14597 alone affected the spikes elicited by the Pf stimulation in none of 26 neurons tested. However, the dopamine-, SKF 38393- and quinpirole-induced inhibition of the spike generation in the Acc neurons was antagonized during simultaneous application of OPC-14597. 5. The firing induced by iontophoretically applied glutamate was inhibited by dopamine, SKF 38393 and quinpirole, but not by OPC-14597. However, the dopamine-, SKF 38393- and quinpirole-induced inhibition of the glutamate-induced firing was also antagonized during simultaneous application of OPC-14597 in a dose-dependent manner in all neurons tested. 6. These findings suggest that OPC-14597 blocks dopaminergic inhibition of the Acc neurons receiving input from the Pf by acting on both D1 and D2 receptors located on the neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708924     DOI: 10.1016/0278-5846(94)00114-w

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.

Authors:  Chiara Rapinesi; Georgios D Kotzalidis; Lorenzo Mazzarini; Roberto Brugnoli; Stefano Ferracuti; Sergio De Filippis; Ilaria Cuomo; Gloria Giordano; Antonio Del Casale; Gloria Angeletti; Gabriele Sani; Paolo Girardi
Journal:  Clin Drug Investig       Date:  2019-08       Impact factor: 2.859

2.  In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

Authors:  A Bortolozzi; L Díaz-Mataix; M Toth; P Celada; F Artigas
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

Review 3.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission.

Authors:  Kouji Fukuyama; Toshiki Hasegawa; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.